Status In progress
Process STA
ID number 1066

Provisional Schedule

Expected publication 03 October 2018

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Merck Sharpe & Dohme (pembrolizumab)
Others Department of Health
  NHS England
  NHS Leicester City CCG
  NHS Newham CCG
  Welsh Government
Patient carer groups Black Health Agency
  Cancer Black Care
  Cancer Equality
  Cancer Laryngectomee Trust
  Cancer52
  Changing Faces
  Get-A-Head
  HAWC
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Let’s Face it
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Mouth Cancer Foundation
  Muslim Council of Britain
  National Association of Laryngectomee Clubs
  Rarer Cancers Foundation
  Specialised Healthcare Alliance
  South Asian Health Foundation
  Swallows Head & Neck Cancer Support Group
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  British Association of Head and Neck Oncologists
  British Association of Head and Neck Oncology Nurses
  British Association of Oral and Maxillofacial Surgeons
  British Association of Otorhinolaryngologists
  British Dietetic Association- Oncology Specialist Group
  British Dental Health Foundation
  British Geriatrics Society
  British Institute of Radiology
  British Oculoplastic Surgery Society
  British Psychosocial Oncology Society
  British Skull Base Society
  Cancer Research UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (carboplatin, cisplatin, docetaxel, methotrexate, paclitaxel)
  Allergan (docetaxel, paclitaxel)
  Bristol-Myers Squibb (nivolumab)
  Celgene (paclitaxel)
  Concordia International (methotrexate)
  Dr. Reddy’s Laboratories (docetaxel)Hameln Pharmaceuticals (methotrexate)
  Hospira UK (carboplatin, cisplatin, docetaxel, methotrexate, paclitaxel)
  Medac GmbH (docetaxel, methotrexate, paclitaxel)
  Nordic Pharma (methotrexate)
  Orion Pharma (methotrexate)
  Pfizer (methotrexate)
General commentators Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association for Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  Scottish Medicines Consortium
Relevant research groups Cochrane Ear, Nose and Throat Disorders Group
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research
  Oracle Cancer Trust

Timeline

Key events during the development of the guidance:

Date Update
03 January 2018 Invitation to participate
07 December 2017 In progress, In progress
18 August 2017 Suspended, Following on from advice received from the company, the timelines for this appraisal are to be confirmed as a pivotal study relevant to this proposed indication has failed to meet its primary endpoint for overall survival. Therefore, NICE has decided to suspend this appraisal from its work programme.
18 August 2017 As you will be aware, the Department of Health has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy. Following on from advice received from the company, the timelines for this appraisal are to be confirmed as a pivotal study relevant to this proposed indication has failed to meet its primary endpoint for overall survival. Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes
03 July 2017 - 31 July 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
22 July 2016 Referral
22 July 2016 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance